MedPath

Effects of a Psycho-cognitive Nursing Intervention on Patients' Outcomes in Critical Illness

Early Phase 1
Conditions
Stress
Inflammatory Response
Critical Illness
Interventions
Behavioral: Massage, Relaxation, Guided imagery and music listening.
Other: No Intervention
Registration Number
NCT02423252
Lead Sponsor
Dr Elizabeth Papathanassoglou
Brief Summary

The purpose of this study is to investigate whether a psycho-cognitive nursing intervention including relaxation, guided imagery, touch and music listening can improve the clinical and psychological outcome of critically ill patients. The investigators hypothesize that, patients who receive the proposed psycho-cognitive nursing intervention will report lower stress, less pain and have altered level of stress neuropeptides in peripheral blood, lower levels of inflammatory molecules, less complications and better self reported lived experience than patients who receive standard care alone.

Detailed Description

In previous research on the impact of stress on physiology, it has been shown that stress and its molecules may contribute to derangements prevalent in critical illness, including systemic inflammation, cellular stress, oxidative damage, endothelial dysfunction and coagulopathies which precipitate high mortality and morbidity. Investigators will examine whether a Psycho-cognitive nursing intervention to induce relaxation can improve patients outcomes.

Sixty ICU patients with or without SIRS will be randomized to receive either standard care or a brief Psycho-cognitive Nursing Intervention, plus standard care, up to 5 days during ICU stay.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Critically ill patients
  • Understand Greek language
  • Age over 18 years
  • They have Richmond Agitation Sedation Scale rate: -3 +3
  • Have an Arterial line in place
Exclusion Criteria
  • Patient who is expected to stay less than 24 hours in Critical care unit
  • Have history of psychiatric disturbances
  • Their condition does not permit use of headphones
  • Have hearing impairment
  • Receive neuro-muscular blockers
  • Are confused
  • Patients under universal conduct precautions

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention groupNo InterventionIntervention: Massage, Relaxation, imagery, music. Patients in Intervention group will receive standard care plus massage, relaxation, guided imagery and music listening
Intervention groupMassage, Relaxation, Guided imagery and music listening.Intervention: Massage, Relaxation, imagery, music. Patients in Intervention group will receive standard care plus massage, relaxation, guided imagery and music listening
Primary Outcome Measures
NameTimeMethod
Change in Pain intensity [10-point numeric rating scale (NRS) scale]from baseline to 60 min over 1-5 days. (baseline: just before 1st day starting intervention time).
Change in Pain intensity [Behavioral pain scale (BPS) scale]from baseline to 60 min over 1-5 days. (baseline: just before 1st day starting intervention time).
Change in Pain intensity [critical-care pain observation tool (CPOT) scale]from baseline to 60 min over 1-5 days. (baseline: just before 1st day starting intervention time).
Change in Systolic blood pressure (SBP)from baseline to 30 and 60 min (baseline: just before 1st day starting intervention time), over 1 to 5 days.
Change in self reported Relaxation/calm levels (self- reported, 10 points NRS scale)from baseline to 60 min (baseline: just before 1st day starting intervention time), over 1 to 5 days.
Change in Plasma Neuropeptide Y levelfrom baseline to 60 min (baseline: morning before 1st day intervention) (1st sample), morning after 1st day intervention (2nd sample), morning before and after intervention (1st and 2nd sample) on days 3rd and 5th.] [Designated as safety issue: No]
Change in Plasma Neuropeptide oxytocin levelfrom baseline to 60 min (baseline: morning before 1st day intervention) (1st sample), morning after 1st day intervention (2nd sample), morning before and after intervention (1st and 2nd sample) on days 3rd and 5th.] [Designated as safety issue: No]
Change in Plasma Neuropeptide beta-endorphin levelfrom baseline to 60 min (baseline: morning before 1st day intervention) (1st sample), morning after 1st day intervention (2nd sample), morning before and after intervention (1st and 2nd sample) on days 3rd and 5th.] [Designated as safety issue: No]
Change in Plasma Neuropeptide acetylcholine levelfrom baseline to 60 min (baseline: morning before 1st day intervention) (1st sample), morning after 1st day intervention (2nd sample), morning before and after intervention (1st and 2nd sample) on days 3rd and 5th.] [Designated as safety issue: No]

Investigators will study the differences of clinical and biochemical parameters between randomized groups of patients treated and not treated with the intervention.

Differences in levels of neuropeptides and inflammatory markers among patient groups (intervention group and comparison) and group of healthy volunteers.

Secondary Outcome Measures
NameTimeMethod
Change in Diastolic blood pressure (DAP)from baseline to 30 and 60 min (baseline: just before 1st day starting intervention time), over 1 to 5 days.
Change in Mean arterial pressure (MAP)from baseline to 30 and 60 min (baseline: just before 1st day starting intervention time),
Change in Heart rate (HR)from baseline to 30 and 60 min (baseline: just before 1st day starting intervention time),

Differences in levels of neuropeptides and inflammatory markers among patient groups (intervention group and comparison) and group of healthy volunteers.

Change in Respiration rate (RR)from baseline to 30 and 60 min (baseline: just before 1st day starting intervention time),
Change in Temperature (TMP)from baseline to 30 and 60 min (baseline: just before 1st day starting intervention time),
Multiple organ disfunction syndrome (MODS) scoresonce on days 1, 3, 5 and on last day of stay in ICU.
Change in Self reported anxiety level [10-point numeric rating scale (NRS) scale]from baseline to 60 min over 1-5 days. (baseline: just before 1st day starting intervention time).
Sequential organ failure assessment (SOFA) scoresonce on days 1, 3, 5 and on last day of stay in ICU.
Change in Self reported fear level [10-point numeric rating scale (NRS)from baseline to 60 min over 1-5 days. (baseline: just before 1st day starting intervention time).
Change in Self reported optimism level [10-point numeric rating scale (NRS)from baseline to 60 min over 1-5 days. (baseline: just before 1st day starting intervention time).
Change in Self reported distress level [10-point numeric rating scale (NRS)]from baseline to 60 min over 1-5 days. (baseline: just before 1st day starting intervention time).
Richmond agitation-sedation scale (RASS) scoredays 1, 2, 3, 4, 5.
Change in Plasma levels of Inflammatory marker Interleukin-6from baseline to 60 min (baseline: morning before 1st day intervention) (1st sample), morning after 1st day intervention (2nd sample), morning before and after intervention (1st and 2nd sample) on days 3rd and 5th.] [Designated as safety issue: No]
Change in Plasma levels of Inflammatory marker Interleukin-8from baseline to 60 min (baseline: morning before 1st day intervention) (1st sample), morning after 1st day intervention (2nd sample), morning before and after intervention (1st and 2nd sample) on days 3rd and 5th.] [Designated as safety issue: No]
Change in Plasma levels of Inflammatory marker soluble fas ligand (sfas)from baseline to 60 min (baseline: morning before 1st day intervention) (1st sample), morning after 1st day intervention (2nd sample), morning before and after intervention (1st and 2nd sample) on days 3rd and 5th.] [Designated as safety issue: No]
Change in Plasma inflammatory marker levels High mobility group box-1 (HMGB-1)]from baseline to 60 min (baseline: morning before 1st day intervention) (1st sample), morning after 1st day intervention (2nd sample), morning before and after intervention (1st and 2nd sample) on days 3rd and 5th.] [Designated as safety issue: No]

Investigators will study the differences of clinical and biochemical parameters between randomized groups of patients treated and not treated with the intervention.

Differences in levels of neuropeptides and inflammatory markers among patient groups (intervention group and comparison) and group of healthy volunteers.

Self reported quality of Sleep [10-point numeric rating scale (NRS) scale]morning before starting intervention (days 1-5)
assessment of psychological distress (ICUESS: Intensive Care Unit Environmental Stressor Scale, self-assessment in a 1-10 numerical analogue scale).within 48 hours post discharge from ICU
Assessment of symptoms of post traumatic stress disorder (PTSD) using DTS (Davidson Trauma Scale)one month and six months after hospital discharge
assessment of quality of life using Short Form 36 version2 scale (SF36v2)one month and six months after discharge
Exploration of lived experience of critical illness (phenomenological interviews)one month and six months after discharge

Trial Locations

Locations (1)

Nicosia General Hospital

🇨🇾

Nicosia, Cyprus

© Copyright 2025. All Rights Reserved by MedPath